Innovent Biologics Inc (6IB) - Total Liabilities

Latest as of December 2025: €17.99 Billion EUR ≈ $21.03 Billion USD

Based on the latest financial reports, Innovent Biologics Inc (6IB) has total liabilities worth €17.99 Billion EUR (≈ $21.03 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Innovent Biologics Inc to track the company's year-over-year net asset growth rate.

Innovent Biologics Inc - Total Liabilities Trend (2016–2025)

This chart illustrates how Innovent Biologics Inc's total liabilities have evolved over time, based on quarterly financial data. See Innovent Biologics Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

Innovent Biologics Inc Competitors by Total Liabilities

The table below lists competitors of Innovent Biologics Inc ranked by their total liabilities.

Company	Country	Total Liabilities
CF Industries Holdings Inc NYSE:CF	USA	$6.35 Billion
NVR Inc NYSE:NVR	USA	$2.07 Billion
Sinopac Financial Holdings Co Ltd TW:2890	Taiwan	NT$2.86 Trillion
Wipro Limited F:WIOA	Germany	€512.90 Billion
Computershare Ltd AU:CPU	Australia	AU$2.86 Billion
JSC National Atomic Company Kazatomprom IL:KAP	UK	$1.24 Trillion
Ovintiv Inc NYSE:OVV	USA	$66.17 Billion
WESCO International Inc NYSE:WCC	USA	$11.87 Billion

Liability Composition Analysis (2016–2025)

This chart breaks down Innovent Biologics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 6IB market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.62	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.93	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.48	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Innovent Biologics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Innovent Biologics Inc (2016–2025)

The table below shows the annual total liabilities of Innovent Biologics Inc from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	€17.99 Billion ≈ $21.03 Billion	+112.04%
2024-12-31	€8.48 Billion ≈ $9.92 Billion	+4.75%
2023-12-31	€8.10 Billion ≈ $9.47 Billion	+18.09%
2022-12-31	€6.86 Billion ≈ $8.02 Billion	+15.99%
2021-12-31	€5.91 Billion ≈ $6.91 Billion	+93.55%
2020-12-31	€3.06 Billion ≈ $3.57 Billion	+23.47%
2019-12-31	€2.47 Billion ≈ $2.89 Billion	+29.00%
2018-12-31	€1.92 Billion ≈ $2.24 Billion	-52.98%
2017-12-31	€4.08 Billion ≈ $4.77 Billion	+8.09%
2016-12-31	€3.77 Billion ≈ $4.41 Billion	--

About Innovent Biologics Inc

F:6IB Germany Biotechnology

Market Cap

$19.20 Billion

€16.42 Billion EUR

Market Cap Rank

#1481 Global

#332 in Germany

Share Price

€9.47

Change (1 day)

-2.63%

52-Week Range

€7.96 - €11.60

All Time High

€11.80